参考文献/References:
[1] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e895-e1032.
[2] Greene SJ,Bauersachs J,Brugts JJ,et al. Worsening heart?failure:nomenclature,epidemiology,and future directions:JACC?Review?Topic of the Week[J]. J Am Coll Cardiol,2023,81(4):413-424.
[3] Wiley SR,Schooley K,Smolak PJ,et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity,1995,3(6):673-682.
[4] Galeone A,Grano M,Brunetti G. Tumor necrosis factor family members and myocardial ischemia-reperfusion injury:state of the art and therapeutic implications[J]. Int J Mol Sci,2023,24(5):4606.
[5] Maji A,Paul A,Sarkar A,et al. Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling:implications for cancer-targeted therapeutics[J]. Biochem Pharmacol,2024,221:116041.
[6] Kahraman S,Yilmaz O,Altunbas HA,et al. TRAIL induces proliferation in rodent pancreatic beta cells via AKT activation[J]. J Mol Endocrinol,2021,66(4):325-338.
[7] Li J,Li X,Zhou S,et al. Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL[J]. Mol Med,2022,28(1):141.
[8] Cartland SP,Patil MS,Kelland E,et al. The generation of stable microvessels in ischemia is mediated by endothelial cell derived TRAIL[J]. Sci Adv,2024,10(40):eadn8760.
[9] Di Cristofano F,George A,Tajiknia V,et al. Therapeutic targeting of TRAIL death receptors[J]. Biochem Soc Trans,2023,51(1):57-70.
[10] Tian X,Srinivasan PR,Tajiknia V,et al. Targeting apoptotic pathways for cancer therapy[J]. J Clin Invest,2024,134(14):e179570.
[11] Bock FJ,Tait SWG. Mitochondria as multifaceted regulators of cell death[J]. Nat Rev Mol Cell Biol,2020,21(2):85-100.
[12] Guerrache A,Micheau O. TNF-related apoptosis-inducing ligand:non-apoptotic signalling[J]. Cells,2024,13(6):521.
[13] Pimentel JM,Zhou JY,Wu GS. The role of TRAIL in apoptosis and immunosurveillance in cancer[J]. Cancers (Basel),2023,15(10):2752.
[14] Vunnam N,Lo CH,Grant BD,et al. Soluble extracellular domain of death receptor 5 inhibits TRAIL-induced apoptosis by disrupting receptor-receptor interactions[J]. J Mol Biol,2017,429(19):2943-2953.
[15] Tanner MA,Grisanti LA. A dual role for death receptor 5 in regulating cardiac fibroblast function[J]. Front Cardiovasc Med,2021,8:699102.
[16] Hall C,Gehmlich K,Denning C,et al. Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease[J]. J Am Heart Assoc,2021,10(5):e019338.
[17] Sheng SY,Li JM,Hu XY,et al. Regulated cell death pathways in cardiomyopathy[J]. Acta Pharmacol Sin,2023,44(8):1521-1535.
[18] Grisanti LA. TRAIL and its receptors in cardiac diseases[J]. Front Physiol,2023,14:1256852.
[19] Koukorava C,Ahmed K,Almaghrabi S,et al. Anticancer drugs and cardiotoxicity:the role of cardiomyocyte and non-cardiomyocyte cells[J]. Front Cardiovasc Med,2024,11:1372817.
[20] Ushakov A,Ivanchenko V,Gagarina A. Heart failure and type 2 diabetes mellitus:neurohumoral,histological and molecular interconnections[J]. Curr Cardiol Rev,2023,19(2):e170622206132.
[21] He W,Zhou L,Xu K,et al. Immunopathogenesis and immunomodulatory therapy for myocarditis[J]. Sci China Life Sci,2023,66(9):2112-2137.
[22] Guo X,Chen Y,Liu Q. Necroptosis in heart disease:molecular mechanisms and therapeutic implications[J]. J Mol Cell Cardiol,2022,169:74-83.
[23] Ceelen D,Voors AA,Tromp J,et al. Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure[J]. Eur J Heart Fail,2022,24(2):308-320.
[24] Dutka M,Bobiński R,Wojakowski W,et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases[J]. Heart Fail Rev,2022,27(4):1395-1411.
[25] Schirone L,Forte M,Palmerio S,et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling[J]. Oxid Med Cell Longev,2017,2017:3920195.
[26] Akhtar SMM,Ali A,Fareed A,et al. Osteoprotegerin (OPG):a potential biomarker for adverse cardiovascular events in stable coronary artery disease[J]. Health Sci Rep,2024,7(7):e2253.
[27] Karhunen V,Gill D,Huang J,et al. The interplay between inflammatory cytokines and cardiometabolic disease:bi-directional mendelian randomisation study[J]. BMJ Med,2023,2(1):e000157.
[28] Kakareko K,Rydzewska-Roso?owska A,Zbroch E,et al. TRAIL and cardiovascular disease-a risk factor or risk marker:a systematic review[J]. J Clin Med,2021,10(6):1252.
[29] Kelland E,Patil MS,Patel S,et al. The prognostic,diagnostic,and therapeutic potential of TRAIL signalling in cardiovascular diseases[J]. Int J Mol Sci,2023,24(7):6725.
[30] Kuang N,Shu B,Yang F,et al. TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events:a systematic review and meta-analysis[J]. J Cardiovasc Pharmacol,2023,81(5):348-354.
[31] Jankowski J,Kozub KO,Kleibert M,et al. The role of programmed types of cell death in pathogenesis of heart failure with preserved ejection fraction[J]. Int J Mol Sci,2024,25(18):9921.
[32] Engel S?llberg A,Helleberg S,Ahmed S,et al. Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension[J]. ESC Heart Fail,2023,10(6):3582-3591.
[33] Wang Y,Zhang H,Wang Z,et al. Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys,pigs,and rats[J]. Sci Transl Med,2020,12(540):eaaw3172.
[34] Wang M,Wei Y,Wang X,et al. TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats[J]. Heart Vessels,2023,38(3):448-458.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(4):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(4):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(4):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(4):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(4):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]